JP5208962B2 - 二環式ピリミジノンおよびその使用 - Google Patents

二環式ピリミジノンおよびその使用 Download PDF

Info

Publication number
JP5208962B2
JP5208962B2 JP2009541695A JP2009541695A JP5208962B2 JP 5208962 B2 JP5208962 B2 JP 5208962B2 JP 2009541695 A JP2009541695 A JP 2009541695A JP 2009541695 A JP2009541695 A JP 2009541695A JP 5208962 B2 JP5208962 B2 JP 5208962B2
Authority
JP
Japan
Prior art keywords
alkyl
hydroxy
oxo
carboxylic acid
pyrimidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2009541695A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010513322A5 (cg-RX-API-DMAC7.html
JP2010513322A (ja
Inventor
エリック・デイル・ジョーンズ
ジョナサン・アラン・ビクター・コーツ
デイビッド・イアン・ローズ
ジョン・ジョセフ・デッドマン
ニコラス・アンドリュー・バンデグラフ
リサ・ジェーン・ウィンフィールド
ネーラナット・ティエントン
ウィリアム・イッサ
ニール・チョイ
キャサリン・マクファーレン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tali Digital Ltd
Original Assignee
Avexa Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2006907283A external-priority patent/AU2006907283A0/en
Application filed by Avexa Ltd filed Critical Avexa Ltd
Publication of JP2010513322A publication Critical patent/JP2010513322A/ja
Publication of JP2010513322A5 publication Critical patent/JP2010513322A5/ja
Application granted granted Critical
Publication of JP5208962B2 publication Critical patent/JP5208962B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2009541695A 2006-12-22 2007-12-21 二環式ピリミジノンおよびその使用 Expired - Fee Related JP5208962B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
AU2006907283A AU2006907283A0 (en) 2006-12-22 Bicyclic pyrimidinones and uses thereof
AU2006907283 2006-12-22
AU2007902479 2007-05-09
AU2007902479A AU2007902479A0 (en) 2007-05-09 Bicyclic pyrimidinones and uses thereof (2)
AU2007903401A AU2007903401A0 (en) 2007-06-25 Bicyclic pyrimidinodes and uses thereof (3)
AU2007903401 2007-06-25
AU2007904114 2007-07-31
AU2007904114A AU2007904114A0 (en) 2007-07-31 Bicyclic pyrimidinones and uses thereof (4)
PCT/AU2007/001980 WO2008077188A1 (en) 2006-12-22 2007-12-21 Bicyclic pyrimidinones and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010129801A Division JP2010222370A (ja) 2006-12-22 2010-06-07 二環式ピリミジノンおよびその使用

Publications (3)

Publication Number Publication Date
JP2010513322A JP2010513322A (ja) 2010-04-30
JP2010513322A5 JP2010513322A5 (cg-RX-API-DMAC7.html) 2010-06-24
JP5208962B2 true JP5208962B2 (ja) 2013-06-12

Family

ID=39562030

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2009541695A Expired - Fee Related JP5208962B2 (ja) 2006-12-22 2007-12-21 二環式ピリミジノンおよびその使用
JP2010129801A Withdrawn JP2010222370A (ja) 2006-12-22 2010-06-07 二環式ピリミジノンおよびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010129801A Withdrawn JP2010222370A (ja) 2006-12-22 2010-06-07 二環式ピリミジノンおよびその使用

Country Status (15)

Country Link
US (3) US8143268B2 (cg-RX-API-DMAC7.html)
EP (2) EP2114903B1 (cg-RX-API-DMAC7.html)
JP (2) JP5208962B2 (cg-RX-API-DMAC7.html)
KR (2) KR20100049698A (cg-RX-API-DMAC7.html)
CN (1) CN101880280B (cg-RX-API-DMAC7.html)
AR (2) AR064517A1 (cg-RX-API-DMAC7.html)
AT (1) ATE496898T1 (cg-RX-API-DMAC7.html)
AU (2) AU2007336703B9 (cg-RX-API-DMAC7.html)
BR (2) BRPI0720564A2 (cg-RX-API-DMAC7.html)
CA (1) CA2673183C (cg-RX-API-DMAC7.html)
DE (1) DE602007012308D1 (cg-RX-API-DMAC7.html)
DK (1) DK2114903T3 (cg-RX-API-DMAC7.html)
MX (1) MX2009006764A (cg-RX-API-DMAC7.html)
NZ (1) NZ577491A (cg-RX-API-DMAC7.html)
WO (1) WO2008077188A1 (cg-RX-API-DMAC7.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011526246A (ja) * 2008-07-02 2011-10-06 アベキサ・リミテッド チアゾピリミジノンおよびその使用
JP2011526248A (ja) * 2008-07-02 2011-10-06 アベキサ・リミテッド 抗ウイルス特性を有する化合物

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8431581B2 (en) * 2008-07-02 2013-04-30 Avexa Limited Imidazopyrimidines and uses thereof
CN102336751A (zh) * 2010-07-16 2012-02-01 爱维艾珂瑟有限公司 新型抗病毒剂
ES2821394T3 (es) 2013-09-12 2021-04-26 Alios Biopharma Inc Compuestos de 7,8-dihidro-3H-pirazino[1,2-b]piridazin-3,5(6H)-diona y usos de los mismos
EP3082820B1 (en) 2013-12-19 2022-07-20 PTC Therapeutics, Inc. Methods for modulating the amount of rna transcripts
CA2979216A1 (en) 2015-03-11 2016-09-15 Alios Biopharma, Inc. Aza-pyridone compounds and uses thereof
EP4249472A3 (en) 2015-05-30 2023-12-13 PTC Therapeutics, Inc. Methods for modulating rna splicing
MX391850B (es) 2015-12-10 2025-03-19 Ptc Therapeutics Inc Compuestos para usarse en el tratamiento o mejoramiento de la enfermedad de huntington
CA3043755A1 (en) 2016-11-28 2018-05-31 Ptc Therapeutics, Inc. Methods for modulating rna splicing
SG11201911615WA (en) 2017-06-05 2020-01-30 Ptc Therapeutics Inc Compounds for treating huntington's disease
BR112019026508A2 (pt) 2017-06-14 2020-07-14 Ptc Therapeutics, Inc. métodos para modificar o splicing do rna
MX2019015580A (es) 2017-06-28 2020-07-28 Ptc Therapeutics Inc Metodos para tratar la enfermedad de huntington.
WO2019005980A1 (en) 2017-06-28 2019-01-03 Ptc Therapeutics, Inc. METHODS OF TREATING HUNTINGTON'S DISEASE
AU2019243048A1 (en) 2018-03-27 2020-10-15 Ptc Therapeutics, Inc. Compounds for treating Huntington's disease
BR112020026534A2 (pt) 2018-06-27 2021-03-23 Ptc Therapeutics, Inc. Compostos de heteroarila para o tratamento da doença de huntington
MX2020014098A (es) 2018-06-27 2021-05-27 Ptc Therapeutics Inc Compuestos heterocíclicos y de heteroarilo para tratar la enfermedad de huntington.
EP3814360B8 (en) 2018-06-27 2024-11-06 PTC Therapeutics, Inc. Heteroaryl compounds for treating huntington's disease
CA3162166A1 (en) 2019-12-02 2021-06-10 Storm Therapeutics Limited Polyheterocyclic compounds as mettl3 inhibitors
US12070445B2 (en) * 2021-08-27 2024-08-27 Wisconsin Alumni Research Foundation System and assay for monitoring production/release of membrane-lytic toxins in bacteria and compounds for modulating same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60107586T2 (de) 2000-09-20 2005-10-06 Schering Corp. Substituierte imidazole als duale histamine h1 und h3 agonisten oder antagonisten
SI1564210T1 (sl) 2002-11-20 2010-01-29 Japan Tobacco Inc 4-oksokinolinske spojine in njihova uporaba kot inhibitorji HIV integraze
JP4915734B2 (ja) 2003-12-18 2012-04-11 テイボテク・フアーマシユーチカルズ 呼吸器合胞体ウイルス複製阻害剤としてのアミノベンズイミダゾールおよびベンズイミダゾール
TW200526635A (en) * 2003-12-22 2005-08-16 Shionogi & Co Hydroxypyrimidinone derivative having HIV integrase inhibitory activity
CN101072758B (zh) 2004-10-12 2013-07-31 阿斯利康(瑞典)有限公司 喹唑啉衍生物
JP5116660B2 (ja) * 2005-03-31 2013-01-09 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・エルレ・エルレ Ｈｉｖインテグラーゼ阻害剤
US7939537B2 (en) * 2005-10-04 2011-05-10 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. HIV integrase inhibitors

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011526246A (ja) * 2008-07-02 2011-10-06 アベキサ・リミテッド チアゾピリミジノンおよびその使用
JP2011526248A (ja) * 2008-07-02 2011-10-06 アベキサ・リミテッド 抗ウイルス特性を有する化合物

Also Published As

Publication number Publication date
US8859563B2 (en) 2014-10-14
ATE496898T1 (de) 2011-02-15
WO2008077188A1 (en) 2008-07-03
CN101880280A (zh) 2010-11-10
DK2114903T3 (da) 2011-04-18
KR20090097194A (ko) 2009-09-15
AR064517A1 (es) 2009-04-08
CA2673183A1 (en) 2008-07-03
US8207334B2 (en) 2012-06-26
HK1131615A1 (en) 2010-01-29
DE602007012308D1 (de) 2011-03-10
JP2010222370A (ja) 2010-10-07
EP2114903A4 (en) 2009-12-30
AU2007336703B2 (en) 2012-04-12
EP2114903B1 (en) 2011-01-26
AU2010201160A1 (en) 2010-04-15
US20110009366A1 (en) 2011-01-13
EP2269992A1 (en) 2011-01-05
AU2007336703A1 (en) 2008-07-03
CN101880280B (zh) 2014-07-16
US8143268B2 (en) 2012-03-27
US20120232035A1 (en) 2012-09-13
NZ577491A (en) 2011-06-30
JP2010513322A (ja) 2010-04-30
KR20100049698A (ko) 2010-05-12
BRPI0720564A2 (pt) 2011-08-16
US20100168063A1 (en) 2010-07-01
EP2114903A1 (en) 2009-11-11
CA2673183C (en) 2014-06-10
AU2007336703B9 (en) 2014-03-27
BRPI0722411A2 (pt) 2012-06-05
MX2009006764A (es) 2009-11-26
AR077043A2 (es) 2011-07-27

Similar Documents

Publication Publication Date Title
JP5208962B2 (ja) 二環式ピリミジノンおよびその使用
JP5535204B2 (ja) 抗ウイルス特性を有する化合物
JP2003321472A (ja) Ｇｒｋ阻害剤
CN105164135A (zh) 4-取代的吡咯并二氮杂卓和吡唑并二氮杂卓
JP2012514044A (ja) Ｒａｆキナーゼ阻害剤として有用なヘテロアリール化合物
CZ194994A3 (en) Piperazine and piperidine derivatives, process of their preparation and pharmaceutical compositions containing thereof
CA2729656A1 (en) Imidazopyrimidinones and uses thereof
WO2017003894A1 (en) Substituted triazolo bicyclic compounds as pde2 inhibitors
CN101627019A (zh) 双环嘧啶酮以及其应用
ES2358550T3 (es) Pirimidinonas bicíclicas y sus usos.
HK1131615B (en) Bicyclic pyrimidinones and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100428

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100428

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120911

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20121210

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20121217

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130110

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130212

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130220

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20160301

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees